Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019_Chinese Journal of Evidence-Based Medicine

Authors：

XIAO Hui , WU Fan , AN Furun ,  ZHAI Zhimin

Department of Hematology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, P. R. China;

Corresponding?author：

ZHAI Zhimin, Email: zzzm889@163.com

Keywords：

Non-Hodgkin's lymphoma; Disease burden; Joinpoint regression; Disability-adjusted life years

DOI：

10.7507/1672-2531.202303171

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the disease burden and development trend of non-Hodgkin lymphoma (NHL) in China from 1990 to 2019. Methods The changes of incidence, mortality, disability-adjusted life years (DALY) and their corresponding age-normalization rates for NHL were analyzed by using the 2019 Global Burden of Disease Database. Regression analysis was performed by Joinpoint software to calculate annual percentage change (APC) and average annual percentage change (AAPC) of standardized morbidity, standardized mortality, standardized DALY rate to reflect the change trend of disease burden. And the results were compared with global data. Results From 1990 to 2019, the disease burden of NHL in China showed an overall increasing trend. Compared with 2019, the standard incidence rate, standard mortality rate and standard DALY rate of NHL in China increased by 144.72%, 27.17% and 15.61%, respectively. The annual rates of change were 3.12%, 0.80% and 0.51%, respectively. There were gender and age differences in disease burden. The burden of disease increased with age, and the burden of disease was higher in males than in females. Conclusion The disease burden of NHL in China shows an increasing trend from 1990 to 2019. With the development of diagnosis and treatment options, the disease burden has decreased in recent years, but it is still higher than the global level. There is still a need to strengthen research on its pathogenesis and treatment options, and to actively intervene in high-risk groups to reduce the disease burden of NHL.

Citation： XIAO Hui, WU Fan, AN Furun, ZHAI Zhimin. Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019. Chinese Journal of Evidence-Based Medicine, 2023, 23(8): 880-886. doi: 10.7507/1672-2531.202303171 Copy

1.	Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet, 2017, 390(10091): 298-310.
2.	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
3.	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791.
4.	Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol, 2019, 12(1): 115.
5.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
6.	GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
7.	屈彥, 王天一, 楊津, 等. GBD數據庫的數據提取方法與流程. 中國循證心血管醫學雜志, 2019, 11(9): 1043-1046.
8.	李茜瑤, 周瑩, 黃輝, 等. 疾病負擔研究進展. 中國公共衛生, 2018, 34(5): 777-780.
9.	李輝章, 杜靈彬. Joinpoint回歸模型在腫瘤流行病學時間趨勢分析中的應用. 中華預防醫學雜志, 2020, 54(8): 908-912.
10.	Chen HS, Zeichner S, Anderson RN, et al. The Joinpoint-jump and Joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics. J Off Stat, 2020, 36(1): 49-62.
11.	胡成如, 王麗, 孫茜, 等. 體重指數與惡性淋巴瘤關系病例對照研究的Meta分析. 中國循證醫學雜志, 2012, 12(1): 55-60.
12.	't Mannetje A, De Roos AJ, Boffetta P, et al. Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Environ Health Perspect, 2016, 124(4): 396-405.
13.	Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014, 2014(48): 130-144.
14.	杜鵬, 李龍. 新時代中國人口老齡化長期趨勢預測. 中國人民大學學報, 2021, 35(1): 96-109.
15.	修冰, 劉輝, 李玉蘭, 等. CAR-T治療B細胞淋巴瘤研究新進展. 臨床內科雜志, 2022, 39(9): 586-589.
16.	Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol, 2022, 23(2): 155-170.
17.	Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet, 2019, 394(10204): 1192-1204.
18.	Yu H. Universal health insurance coverage for 1.3 billion people:what accounts for China's success? Health Policy, 2015, 119(9): 1145-1152.
19.	Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990—2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY), 2022, 14(7): 3175-3190.
20.	Cai W, Zeng Q, Zhang X, et al. Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990—2019: results from the Global Burden of Disease Study 2019. Front Med (Lausanne), 2021, 8: 738693.
21.	Pfreundschuh M. Age and sex in non-Hodgkin lymphoma therapy: it's not all created equal, or is it. Am Soc Clin Oncol Educ Book, 2017, 37: 505-511.
22.	Crozier JA, Sher T, Yang D, et al. Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review. Clin Lymphoma Myeloma Leuk, 2015, 15(10): 578-585.
23.	鄭湧智, 陳再生, 華雪玲, 等. 兒童不同病理亞型非霍奇金淋巴瘤的臨床特征及預后因素. 中國實驗血液學雜志, 2020, 28(2): 500-506.
24.	Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 589-597.
25.	Howlader N, Morton LM, Feuer EJ, et al. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 174-179.
26.	中國抗癌協會淋巴瘤專業委員會, 中國醫師協會腫瘤醫師分會, 中國醫療保健國際交流促進會腫瘤內科分會. 中國淋巴瘤治療指南(2021年版). 中華腫瘤雜志, 2021, 43(7): 707-735.

1. Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet, 2017, 390(10091): 298-310.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
3. Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791.
4. Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol, 2019, 12(1): 115.
5. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
6. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
7. 屈彥, 王天一, 楊津, 等. GBD數據庫的數據提取方法與流程. 中國循證心血管醫學雜志, 2019, 11(9): 1043-1046.
8. 李茜瑤, 周瑩, 黃輝, 等. 疾病負擔研究進展. 中國公共衛生, 2018, 34(5): 777-780.
9. 李輝章, 杜靈彬. Joinpoint回歸模型在腫瘤流行病學時間趨勢分析中的應用. 中華預防醫學雜志, 2020, 54(8): 908-912.
10. Chen HS, Zeichner S, Anderson RN, et al. The Joinpoint-jump and Joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics. J Off Stat, 2020, 36(1): 49-62.
11. 胡成如, 王麗, 孫茜, 等. 體重指數與惡性淋巴瘤關系病例對照研究的Meta分析. 中國循證醫學雜志, 2012, 12(1): 55-60.
12. 't Mannetje A, De Roos AJ, Boffetta P, et al. Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Environ Health Perspect, 2016, 124(4): 396-405.
13. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014, 2014(48): 130-144.
14. 杜鵬, 李龍. 新時代中國人口老齡化長期趨勢預測. 中國人民大學學報, 2021, 35(1): 96-109.
15. 修冰, 劉輝, 李玉蘭, 等. CAR-T治療B細胞淋巴瘤研究新進展. 臨床內科雜志, 2022, 39(9): 586-589.
16. Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol, 2022, 23(2): 155-170.
17. Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet, 2019, 394(10204): 1192-1204.
18. Yu H. Universal health insurance coverage for 1.3 billion people:what accounts for China's success? Health Policy, 2015, 119(9): 1145-1152.
19. Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990—2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY), 2022, 14(7): 3175-3190.
20. Cai W, Zeng Q, Zhang X, et al. Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990—2019: results from the Global Burden of Disease Study 2019. Front Med (Lausanne), 2021, 8: 738693.
21. Pfreundschuh M. Age and sex in non-Hodgkin lymphoma therapy: it's not all created equal, or is it. Am Soc Clin Oncol Educ Book, 2017, 37: 505-511.
22. Crozier JA, Sher T, Yang D, et al. Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review. Clin Lymphoma Myeloma Leuk, 2015, 15(10): 578-585.
23. 鄭湧智, 陳再生, 華雪玲, 等. 兒童不同病理亞型非霍奇金淋巴瘤的臨床特征及預后因素. 中國實驗血液學雜志, 2020, 28(2): 500-506.
24. Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 589-597.
25. Howlader N, Morton LM, Feuer EJ, et al. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 174-179.
26. 中國抗癌協會淋巴瘤專業委員會, 中國醫師協會腫瘤醫師分會, 中國醫療保健國際交流促進會腫瘤內科分會. 中國淋巴瘤治療指南(2021年版). 中華腫瘤雜志, 2021, 43(7): 707-735.

Chinese Journal of Evidence-Based Medicine

Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content